Nanoparticles engineered with rituximab and loaded with nutlin-3 show promising therapeutic activity in B-leukemic xenografts

Clinical Cancer Research

Volumn 19, Issue 14, 2013, Pages 3871-3880

  Voltan, Rebecca ^a   Secchiero, Paola ^a   Ruozi, Barbara ^b   Forni, Flavio ^b   Agostinis, Chiara ^c   Caruso, Lorenzo ^c   Vandelli, Maria Angela ^b   Zauli, Giorgio ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; NUTLIN 3; POLYGLACTIN; PROTEIN P53; RITUXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NANOENCAPSULATION; NANOENGINEERING; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMPLEMENT ACTIVATION; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE, SCID; NANOCAPSULES; PARTICLE SIZE; PIPERAZINES; POLYGLACTIN 910; SURFACE PROPERTIES; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881155789     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0015     Document Type: Article

References (37)

1. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8.
2. Secchiero P, di Iasio MG, Gonelli A, Zauli G. The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr Pharm Des 2008;14:2100-10.
3. Secchiero P, Bosco R, Celeghini C, Zauli G. Recent advances in the therapeutic perspectives in nutlin-3. Curr Pharm Des 2011;17:569-77.
4. McCormack E, Haaland I, Venas G, Forthun RB, Huseby S, Gausdal G, et al. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia 2012;26:910-7.
5. Tovar C, Higgins B, Kolinsky K, Xia M, Packman K, Heimbrook DC, et al. MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer. Mol Cancer 2011;10:49.
6. Bai F, Zhu F, Tagen M, Miller L, Owens TS, Mallari J, et al. Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). J Pharm Biomed Anal 2010;51:915-22.
7. Zhang F, Tagen M, Throm S, Mallari J, Miller L, Guy RK, et al. Wholebody physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Dispos 2011;39:15-21.
8. Das M, Sahoo SK. Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy. Acta Biomater 2011;7:355-69.
9. Das M, Sahoo SK. Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS One 2012;7:e32920.
10. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V. PLGAbased nanoparticles: an overview of biomedical applications. J Control Rel 2012;161:505-22.
11. Mukerjee A, Ranjan AP, Vishwanatha JK. Combinatorial nanoparticles for cancer diagnosis and therapy. Curr Med Chem 2012;19:3714-21.
12. Robak T. Rituximab for chronic lymphocytic leukemia. Expert Opin Biol Ther 2012;12:503-5.
13. Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2012;11:CD008079.
14. SantanamU, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci USA 2010;107:12210-15.
15. Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, de Frias M, et al. In vitro and in vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin Cancer Res 2010;16:2046-54.
16. Zauli G, Voltan R, Bosco R, Melloni E, Marmiroli S, Rigolin GM, et al. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Clin Cancer Res 2011;17:762-70.
17. Voltan R, di Iasio MG, Bosco R, Valeri N, Pekarski Y, Tiribelli M, et al. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells. Clin Cancer Res 2011;17:5649-55.
18. Mainardes RM, Evangelista RC. Praziquantel-loaded PLGA nanoparticles: preparation and characterization. J Microencapsul 2005;22: 13-24.
19. Bondioli L, Costantino L, Ballestrazzi A, Lucchesi D, Boraschi D, Pellati F, et al. PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid. Biomaterials 2010;31:3395-403.
20. Nobs L, Buchegger F, Gurny R, Allemann E. Surface modification of poly-lactide acid nanoparticles by covalent attachment of thiol groups by means of three methods. Int J Pharm 2003;250:327-37.
21. Nobs L, Buchegger F, Gurny R, Allemann E. Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin for active targeting. Eur J Pharm Biopharm 2004;58:483-90.
22. Borgatti P, Mazzoni M, Carini C, Neri LM, Marchisio M, Bertolaso L, et al. Changes of nuclear protein kinase C activity and isotype composition in PC12 cell proliferation and differentiation. Exp Cell Res 1996;224:72-8.
23. Milani D, Mazzoni M, Borgatti P, Zauli G, Cantley L, Capitani S. Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells. J Biol Chem 1996;271:22961-4.
24. Zauli G, Re MC, Furlini G, Giovannini M, La Placa M. Human immunodeficiency virus type 1 envelope glycoprotein gp120-mediated killing of human haematopoietic progenitors (CD34+ cells). J Gen Virol 1992;73:417-21.
25. Zauli G, Vitale M, Gibellini D, Capitani S. Inhibition of purified CD34 +hematopoietic progenitor cells by human immunodeficiency virus 1 or gp120 mediated by endogenous transforming growth factor b1. J Exp Med 1996;183:99-108.
26. Vitale M, Zamai L, Falcieri E, Zauli G, Gobbi P, Santi S, et al. IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells. Cytometry 1887;30:61-6.
27. Campioni D, Corallini A, Zauli G, Possati L, Altavilla G, Barbanti- Brodano G. HIV type 1 extracellular tat protein stimulates growth and protects cells of BK virus/tat transgenic mice from apoptosis. AIDS Res Hu Retrov 1995;11:1039-48.
28. Secchiero P, Sblattero D, Chiaruttini C, Melloni E, Macor P, Zorzet S, et al. Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic activity. Int J Immunopathol Pharmacol 2009;22:73-83.
29. Bellosillo B, Villamor N, Lopez-Guillermo A, Marce S, Esteve J, Campo E, et al. Complement-mediated cell death induced by rituximab in Bcell lymphoproliferative disorders is mediated in vitro by a caspaseindependent mechanism involving the generation of reactive oxygen species. Blood 2001;98:2771-7.
30. Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev 2007;59:718-28.
31. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 2011;63:170-83.
32. Biffi S, Garrovo C, Macor P, Tripodo C, Zorzet S, Secco E, et al. In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using timedomain near-infrared optical imaging. Mol Imaging 2008;7: 272-82.
33. Kreuter J. Nanoparticles- a historical perspective. Int J Pharm 2007; 331:1-10.
34. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004;56:1649-59.
35. Debotton N, Parnes M, Kadouche J, Benita S. Overcoming the formulation obstacles towards targeted chemotherapy: in vitro and in vivo evaluation of cytotoxic drug loaded immunonanoparticles. J Control Release 2008;127:219-30.
36. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004;377:159-69.
37. Chellat F, Merhi Y, Moreau A, Yahia L. Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials 2005;26:7260-75.